Gerardo Miguel Munoz-monaco, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2810 W Expressway 83, Mercedes, TX 78570 Phone: 956-973-3531 Fax: 956-973-3570 |
Eduardo Caballero, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 520 W 3rd St, Mercedes, TX 78570 Phone: 956-565-1872 Fax: 956-565-6581 |
Dr. Atanacio Gomez, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2810 W Expressway 83, Mercedes, TX 78570 Phone: 956-296-1831 Fax: 956-296-2970 |
Indira Lizzeth Perales Trejo, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2810 W Expressway 83, Mercedes, TX 78570 Phone: 956-973-3531 |
Jose Rodriguez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2810 W Expressway 83, Mercedes, TX 78570 Phone: 956-734-9067 Fax: 956-734-9068 |
Carlos Arnaldo Medina, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 W 1st St, Mercedes, TX 78570 Phone: 956-565-3191 Fax: 956-787-2021 |
Dr. Rahul Jacob Thomas, MD Family Medicine - Adult Medicine Medicare: Not Enrolled in Medicare Practice Location: Ut Health Rgv - Knapp Family Health Center, 2810 W Expy 83, Mercedes, TX 78570 Phone: 956-296-1816 |
News Archive
Long after a COVID-19 vaccination is developed and years after the coronavirus death toll is tallied, the impact on mental health will linger, continuing to inflict damage if not addressed, according to new research.
Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.
Financial stress can have an immediate impact on well-being, but can it lead to physical pain nearly 30 years later? The answer is yes, according to new research from University of Georgia scientists.
Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual property estate.
› Verified 2 days ago